Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study

Overview

Journal Dermatol Ther (Heidelb)

Date 2025 Jan 25

PMID 39862316

Authors

Ersilia Tolino

Luca Ambrosio

Nicoletta Bernardini

Ilaria Proietti

Nevena Skroza

Concetta Potenza

Affiliations

Soon will be listed here.

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.

Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed. Clinical and demographic data were collected, and outcomes were assessed using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and numeric rating scales (NRS) for pruritus and sleep disturbances.

Results: By week 16, 60% achieved a 75% improvement in EASI (EASI75) and 31% reached a 90% improvement in EASI (EASI90), reflecting substantial clinical improvements. A ≥ 4-point reduction in pruritus NRS was observed in 63% of patients by week 16, increasing to 70% by week 32. Similarly, 75% achieved significant improvements in sleep disturbance NRS by week 16, with sustained effects through week 32. Subgroup analysis revealed superior clinical responses in patients with early-onset AD and atopic comorbidities. Lower total immunoglobulin E (IgE) levels at week 16 correlated with better outcomes, suggesting total IgE as a potential biomarker. By week 32, 70% of patients had a DLQI ≤ 5, indicating minimal quality-of-life impact. Additionally, 88% reached at least one therapeutic target, and 81% met composite endpoints combining clinician-assessed and patient-reported outcomes. The safety profile was consistent with clinical trials, with mild conjunctivitis and injection site reactions as the most common adverse events.

Conclusion: These findings support tralokinumab as an effective and well-tolerated treatment, emphasizing the importance of phenotype-specific approaches in AD management.

References

De Greef A, Ghislain P, Bulinckx A, Coster A, de Halleux C, Damsin T . Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study. Clin Drug Investig. 2023; 43(4):299-306. PMC: 10097792. DOI: 10.1007/s40261-023-01258-7. View

Ribero S, Puglisi B, Giura M, Viola R, Siliquini N, Quaglino P . Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Dermatol. 2021; 30(11):1717-1718. DOI: 10.1111/exd.14368. View

Yoshida T, Beck L, Benedetto A . Skin barrier defects in atopic dermatitis: From old idea to new opportunity. Allergol Int. 2021; 71(1):3-13. PMC: 8934597. DOI: 10.1016/j.alit.2021.11.006. View

Thompson A, Anisimowicz Y, Miedema B, Hogg W, Wodchis W, Aubrey-Bassler K . The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016; 17:38. PMC: 4815064. DOI: 10.1186/s12875-016-0440-0. View

Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm W, Pauser S, Da Rosa J . Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024; 79(6):1560-1572. DOI: 10.1111/all.16108. View

Leung D, Ong P . Dupilumab nonresponders in atopic dermatitis. Ann Allergy Asthma Immunol. 2022; 129(3):267-268. DOI: 10.1016/j.anai.2022.05.029. View

Gittler J, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz K, Wang C . Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012; 130(6):1344-54. PMC: 3991245. DOI: 10.1016/j.jaci.2012.07.012. View

Gargiulo L, Ibba L, Vignoli C, Facheris P, Valenti M, Costanzo A . Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatolog Treat. 2023; 34(1):2216815. DOI: 10.1080/09546634.2023.2216815. View

Ellis C, Mancini A, Paller A, Simpson E, Eichenfield L . Understanding and managing atopic dermatitis in adult patients. Semin Cutan Med Surg. 2012; 31(3 Suppl):S18-22. DOI: 10.1016/j.sder.2012.07.006. View

10.

Patruno C, Potestio L, Napolitano M . Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022; 22(4):242-249. DOI: 10.1097/ACI.0000000000000837. View

11.

Baurecht H, Ruhlemann M, Rodriguez E, Thielking F, Harder I, Erkens A . Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018; 141(5):1668-1676.e16. DOI: 10.1016/j.jaci.2018.01.019. View

12.

Simpson E, Merola J, Silverberg J, Reich K, Warren R, Staumont-Salle D . Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022; 187(6):888-899. PMC: 10091996. DOI: 10.1111/bjd.21867. View

13.

Chiricozzi A, Gori N, Di Nardo L, Antonelli F, Caruso C, Caldarola G . Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. Dermatology. 2021; 238(4):717-724. DOI: 10.1159/000519361. View

14.

Park C, Kim S, Lee K, Bieber T . Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. EBioMedicine. 2024; 103:105121. PMC: 11021839. DOI: 10.1016/j.ebiom.2024.105121. View

15.

Silverberg J, Toth D, Bieber T, Alexis A, Elewski B, Pink A . Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020; 184(3):450-463. PMC: 7986183. DOI: 10.1111/bjd.19573. View

16.

Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C . Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013; 132(2):361-70. PMC: 3991240. DOI: 10.1016/j.jaci.2013.04.046. View

17.

Wollenberg A, Howell M, Guttman-Yassky E, Silverberg J, Kell C, Ranade K . Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2018; 143(1):135-141. DOI: 10.1016/j.jaci.2018.05.029. View

18.

Port L, Brunner P . Management of Atopic Hand Dermatitis. Dermatol Clin. 2024; 42(4):619-623. DOI: 10.1016/j.det.2024.06.002. View

19.

Fania L, Moretta G, Antonelli F, Scala E, Abeni D, Albanesi C . Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets. Int J Mol Sci. 2022; 23(5). PMC: 8910412. DOI: 10.3390/ijms23052684. View

20.

Tokura Y, Hayano S . Subtypes of atopic dermatitis: From phenotype to endotype. Allergol Int. 2021; 71(1):14-24. DOI: 10.1016/j.alit.2021.07.003. View